Vident Investment Advisory’s Bicycle Therapeutics BCYC Stock Holding History

Vident Investment Advisory’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-24,287	Closed	-$517K	–	1192
2023 Q1	$517K	Buy	24,287 +330	+1%	+$8.28K	0.02%	770
2022 Q4	$709K	Buy	+23,957	New	+$643K	0.03%	592
2022 Q2	–	Sell	-21,572	Closed	-$947K	–	1282
2022 Q1	$947K	Buy	21,572 +3,639	+20%	+$170K	0.02%	708
2021 Q4	$1.09M	Buy	+17,933	New	+$989K	0.03%	670

Other funds holding BCYC

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vident Investment Advisory's BCYC Position: Q2 2023 in Review

Vident Investment Advisory sold out of Bicycle Therapeutics (BCYC) in Q2 2023, closing a stake of 24,287 shares — an estimated $517K sold.

Vident Investment Advisory first reported a position in BCYC in Q4 2021 and held it in 4 quarters. The position peaked at $1.09M in Q4 2021. 85 funds tracked by Wall St. Rank hold BCYC as of Q2 2023.

Vident Investment Advisory reported no remaining Bicycle Therapeutics position as of Q2 2023 after selling out during the quarter.
Vident Investment Advisory sold 24,287 Bicycle Therapeutics shares in Q2 2023, an estimated $517K.
Vident Investment Advisory first reported a position in Bicycle Therapeutics in Q4 2021 and held it in 4 quarters.
Vident Investment Advisory's Bicycle Therapeutics position peaked at $1.09M in Q4 2021.
85 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.